Syncom Formulations India Ltd Stock Price Today (NSE: SYNCOMF)
Fundamental Score
Syncom Formulations India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Syncom Formulations India Ltd share price today is ₹14.22, down 0.97% on NSE/BSE as of 17 June 2026. Syncom Formulations India Ltd (SYNCOMF) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.46K (Cr). The 52-week high for SYNCOMF share price is ₹21.25 and the 52-week low is ₹10.21. At a P/E ratio of 23.28x, SYNCOMF is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.50% and a debt-to-equity ratio of 0.00.
Syncom Formulations India Ltd Share Price Chart — NSE/BSE Historical Performance
Syncom Formulations India Ltd share price chart: 11.27% return over the past month. 52-week high ₹21.25, 52-week low ₹10.21.
Syncom Formulations India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹14.75 | ₹15.09 | ₹14.45 | ₹14.93 | 24.71L (Cr) | |
| ₹15.01 | ₹15.38 | ₹14.71 | ₹14.77 | 27.45L (Cr) | |
| ₹15.60 | ₹15.66 | ₹14.92 | ₹15.01 | 30.53L (Cr) | |
| ₹15.60 | ₹15.60 | ₹15.60 | ₹15.60 | 0.00 (Cr) | |
| ₹16.04 | ₹16.40 | ₹15.51 | ₹15.60 | 39.05L (Cr) | |
| ₹16.00 | ₹16.39 | ₹15.90 | ₹16.00 | 52.18L (Cr) | |
| ₹14.62 | ₹16.56 | ₹14.62 | ₹15.85 | 266.90L (Cr) | |
| ₹14.39 | ₹14.49 | ₹14.19 | ₹14.34 | 16.09L (Cr) | |
| ₹14.14 | ₹14.65 | ₹14.11 | ₹14.26 | 15.32L (Cr) | |
| ₹14.01 | ₹14.34 | ₹13.93 | ₹14.11 | 18.37L (Cr) |
Syncom Formulations India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹15.01 | ₹15.38 | ₹14.45 | ₹14.93 | -0.53% | |
| ₹13.74 | ₹16.56 | ₹13.21 | ₹15.01 | +9.24% | |
| ₹10.70 | ₹14.43 | ₹10.47 | ₹13.74 | +28.41% | |
| ₹11.62 | ₹12.60 | ₹10.21 | ₹10.30 | -11.36% | |
| ₹13.90 | ₹14.83 | ₹11.53 | ₹12.79 | -7.99% | |
| ₹14.26 | ₹14.70 | ₹11.65 | ₹12.96 | -9.12% | |
| ₹15.60 | ₹15.85 | ₹14.02 | ₹14.26 | -8.59% | |
| ₹16.37 | ₹17.25 | ₹15.35 | ₹15.63 | -4.52% | |
| ₹16.14 | ₹17.40 | ₹16.00 | ₹16.44 | +1.86% | |
| ₹16.97 | ₹18.70 | ₹16.03 | ₹16.14 | -4.89% | |
| ₹18.30 | ₹18.86 | ₹16.45 | ₹16.73 | -8.58% | |
| ₹19.34 | ₹19.50 | ₹17.37 | ₹18.19 | -5.95% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Syncom Formulations India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Syncom Formulations India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SYNCOMF across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (15.50%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.59%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.28 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (53.79%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.66%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.51% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.05% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (27.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (105.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-10.56 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.10%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Syncom Formulations India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Syncom Formulations India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Syncom Formulations India LtdSyncom Formulat...Selected✓ SYNCOMF • 524470 | 62.3/100 | ₹14.22₹14 | ₹1462.64₹1462.64 | 23.28Average 23.3 Average | 15.50%Good 15.50% Good | 18.59%Good 18.59% Good | 0.00Excellent 0.0 Excellent | 27.71%Excellent 27.71% Excellent | 17.51%Excellent 17.51% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Syncom Formulations India Ltd PE Ratio History
Historical price-to-earnings ratio for SYNCOMF — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.57 | ₹14.26 | 25x |
| FY 2024 | ₹0.34 | ₹20.00 | 58.8x |
| FY 2023 | ₹0.22 | ₹15.05 | 69.6x |
| FY 2022 | ₹0.24 | ₹8.85 | 36.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Syncom Formulations India Ltd Dividend History
Annual cash dividends paid by SYNCOMF — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹2.82 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Syncom Formulations India Ltd Quarterly Performance
Latest quarterly metrics for SYNCOMF — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
53.79%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
17.51%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
27.71%
Compounded annual net profit growth over 5 years
Syncom Formulations India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SYNCOMF — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Syncom Formulations India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Syncom Formulations India Ltd (SYNCOMF) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Syncom Formulations India Ltd
About SYNCOMF (Syncom Formulations India Ltd)
Syncom Formulations India Ltd is a dynamic pharmaceutical company forging a path in the global healthcare landscape. With a foundation built on quality and innovation, Syncom manuf...actures and distributes a diverse portfolio of pharmaceutical formulations designed to address a wide spectrum of medical needs. The company’s commitment to research and development drives the creation of effective and accessible healthcare solutions, catering to both domestic and international markets. Syncom Formulations strives to improve the well-being of individuals across the globe by providing reliable and affordable medications that adhere to stringent quality standards and regulatory requirements. The company’s operational framework encompasses several strategic business divisions, including pharmaceutical manufacturing, commodity trading, and property rentals, which contribute to a well-rounded and diversified business model. Within the pharmaceutical segment, Syncom Formulations specializes in a comprehensive array of therapeutic categories, ranging from treatments for common ailments to specialized formulations addressing specific health concerns. Their product offerings include a variety of dosage forms such as tablets, capsules, syrups, and injectables, ensuring versatility in meeting the diverse needs of patients and healthcare professionals. Syncom is dedicated to maintaining excellence in every aspect of its operations, from product development to supply chain management. Syncom Formulations is committed to delivering value to its stakeholders through sustainable growth and responsible business practices. As a forward-thinking pharmaceutical company, Syncom embraces technological advancements and innovative strategies to enhance its manufacturing processes, expand its market reach, and strengthen its competitive position. Through a focus on customer satisfaction, product quality, and ethical conduct, Syncom Formulations endeavors to build lasting relationships with its partners and contribute positively to the healthcare industry. The company aims to remain at the forefront of pharmaceutical innovation, providing reliable and impactful healthcare solutions that improve lives worldwide.
Company Details
Key Leadership
SYNCOMF Share Price: Frequently Asked Questions
What is the current share price of Syncom Formulations India Ltd?
Syncom Formulations India Ltd (SYNCOMF) trades at ₹14.22 on NSE and BSE. Market cap ₹1.46K (Cr). Educational data only.
What is the P/E ratio of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a P/E of 23.28x vs industry average 31.77x.
What is the Bull Run score for Syncom Formulations India Ltd?
Syncom Formulations India Ltd has a Bull Run score of 62.3/100 based on 25+ financial parameters.
Does Syncom Formulations India Ltd pay dividends?
Syncom Formulations India Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has ROE of 15.50%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Syncom Formulations India Ltd?
Syncom Formulations India Ltd has debt-to-equity of 0.00.
Is Syncom Formulations India Ltd a good investment?
Bull Run gives Syncom Formulations India Ltd a score of 62.3/100. This is not investment advice — consult a SEBI-registered advisor.